These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 29438592)

  • 1. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
    Bolton EM; Lynch T
    BJU Int; 2018 Sep; 122(3):371-383. PubMed ID: 29438592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
    Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
    Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety.
    Raja T; Sud R; Addla S; Sarkar KK; Sridhar PS; Talreja V; Jain M; Patil K
    Indian J Cancer; 2022 Mar; 59(Supplement):S142-S159. PubMed ID: 35343198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
    Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
    BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
    Merseburger AS; Hupe MC
    Adv Ther; 2016 Jul; 33(7):1072-93. PubMed ID: 27246172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptorelin in the management of prostate cancer.
    Ploussard G; Mongiat-Artus P
    Future Oncol; 2013 Jan; 9(1):93-102. PubMed ID: 23252566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients.
    Novara G; Galfano A; Secco S; Ficarra V; Artibani W
    Urol Int; 2009; 82(3):249-55. PubMed ID: 19440008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer.
    Kuhn JM; Abourachid H; Brucher P; Doutres JC; Fretin J; Jaupitre A; Jorest R; Lambert D; Petit J; Pin J; Blumberg J; Dufour-Esquerré F
    Eur Urol; 1997; 32(4):397-403. PubMed ID: 9412795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
    Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
    Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
    Shore ND; Sieber P; Schimke L; Perzin A; Olsen S
    Urol Nurs; 2013; 33(5):236-44, 248. PubMed ID: 24354113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
    Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
    Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eligard: leuprolide acetate in a novel sustained-release delivery system.
    Sartor O
    Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries.
    Cicione A; Nacchia A; Guercio A; Gravina C; Franco A; Grimaldi MC; Tema G; Lombardo R; Tubaro A; De Nunzio C
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):765-771. PubMed ID: 36641533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.